HOTH News and Press, Hoth Therapeutics Inc. From 01/28/21

Hoth Therapeutics (HOTH) announces extension of its research collaboration agreement with Weill Cornell Medicine to continue investigating the therapeutic mechanism of action and safety of HT-003, a novel retinoic acid metabolism blocking agent, for the treatment of acne.The 1-year agree...

Hoth Therapeutics Expands Research Collaboration Agreement with Weill Cornell Medicine to Continue the Advancement of HT-003 for Acne Treatment Research The extended research agreement builds on the positive results generated for HT-003 as an acne therapeutic PR Newswire ...

Hoth Therapeutics Announces the Appointment of Mario E. Lacouture, M.D. to Oversee Dermatology Therapeutic Program for Cancer Patients as Part of Hoth Scientific Advisory Board Dr. Lacouture will oversee the development of Hoth's Proprietary HT-001 for patients receiving EGFR in...

Hoth Therapeutics (HOTH) gains 8% in premarket in reaction to new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.Data fr...

Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication Initial data reports one of the most critical signaling pathways for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003 ...

Acorda Therapeutics (ACOR) +54% after announcing agreement for sale of manufacturing operations and long-term global supply agreement.Summit Midstream Partners (SMLP) +45% after winning FERC construction OK.WiMi Hologram Cloud (WIMI) +38% on obtaining a patent for a 3D holograp...

Hoth Therapeutics' (HOTH) jumps 15% premarket in reaction to the announcement that its Pre-IND meeting requested on Dec. 22 for HT-001 with the FDA has been granted to receive written responses that are targeted for delivery on February 22, 2021. The Pre-IND meeting topics incl...

FDA Grants Hoth Therapeutics Pre-IND Meeting Regarding Proposed Drug Development Plan for HT-001 Treatment for Cancer Patients PR Newswire NEW YORK , Jan. 13, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today ann...

Hoth Therapeutics (HOTH) announces an agreement with Charles River Laboratories (CRL) to initiate preclinical studies of HT-001, a topical formulation designed for the treatment of rash and skin disorders associated with initial and repeat EGFR inhibitor cancer treatment.Together with Ch...

Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients PR Newswire NEW YORK , Jan. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with Charles River ...